General Announcement::Glenmark concludes post marketing surveillance (PMS) study on Favipiravir in 1000+ COVID patients
Issuer & Securities
Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No
Announcement Details
Announcement Title
General Announcement
Date &Time of Broadcast
15-Sep-2021 16:10:26
Status
New
Announcement Sub Title
Glenmark concludes post marketing surveillance (PMS) study on Favipiravir in 1000+ COVID patients
Announcement Reference
SG210915OTHR74PT
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals Limited
Designation
Company Secretary & Compliance Officer
Effective Date and Time of the event
15/09/2021 00:00:00
Description (Please provide a detailed description of the event in the box below)
Glenmark concludes post marketing surveillance (PMS) study on Favipiravir (FabiFlu) in 1000+ COVID-19 patients, findings reinforce the drug's safety and efficacy in real world settings
Attachments
SGX_PR_15092021.pdf
Total size =1540K
Related Announcements
Related Announcements